Section Arrow
ABVX.NASDAQ
- Abivax SA
Quotes are at least 15-min delayed:2026/06/25 01:35 EDT
Regular Hours
Last
 92.51
-5.92 (-6.01%)
Day High 
98.46 
Prev. Close
98.43 
1-M High
135.075 
Volume 
6.73M 
Bid
92.5
Ask
93.2
Day Low
74.79 
Open
97.94 
1-M Low
69.81 
Market Cap 
7.85B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 99.33 
20-SMA 105.6 
50-SMA 113.3 
52-W High 148.83 
52-W Low 7.41 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.61/-2.31
Enterprise Value
7.85B
Balance Sheet
Book Value Per Share
6.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0095-0.0322-77.22%-- 
CALCCalciMedica0.5973-0.206-25.64%-- 
ABSIAbsci Corp10.075+2.665+35.96%-- 
EVGNEvogene Ltd.0.4392-0.0518-10.55%-- 
HUMAHumacyte0.6977-0.0027-0.39%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.